RCAS1 Antibody





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

	Reactivity: H M R Mk	Sensitivity: Endogenous	MW (kDa): 32	Source/Isotype: Rabbit	UniProt ID: #O00559	Entrez-Gene Id: 9166
Product Usage Information		Application Western Blotting Immunoprecipitation Immunofluorescence Flow Cytometry (Fixed	(Immunocytochem	istry)		Dilution 1:1000 1:200 1:800 1:100
Storage		Supplied in 10 mM so 20°C. Do not aliquot t), 150 mM NaCl, 100 μg,	/ml BSA and 50% g	lycerol. Store at –
Specificity/Sensiti	vity	RCAS1 Antibody recog	nizes endogenous	levels of total RCAS1 pro	otein.	
Source / Purificati	on		Gly147 of human R	munizing animals with a CAS1 protein. Antibodie		
Background		binding fragment-assi RCAS1 was recently for regulating the cytolyti and is ubiquitously ex expression of RCAS1 is tract, liver, lung, breas RCAS1 tissue expressi aforementioned malig levels of RCAS1 in the cancer cells and funct lymphocytes, inducing Subsequent studies have regulate vesicle forma RCAS1 overexpression protein trafficking froo delays vesicle transpo glycosylation machine associated glycan anti	ociated gene 9 (EBA bund to play a novel ic activity of cytotox pressed in most hu s increased in a vari on are negatively co gnancies (4). It is als sera of cancer patie ioned as a ligand fc g their apoptosis, w ave identified RCAS ation, secretion, and n negatively regulat m the <i>trans</i> -Golgi to rt from the ER to Ge ery to mislocalize. A igens on the cell su	ed on SiSo cells (RCAS1) G9). Originally identified role in the adaptive imr ic T lymphocytes (CTLs) man tissues and cells (3, ety of malignancies, inc um, and cervix. Researc orrelated with the progn o noteworthy that resea ents (4). Initial studies in r a putative receptor ex- hich enabled cancer cell 1 as a type III transmem I protein glycosylation (2 es the cytolytic function o secretory lysosomes (2 olgi and causes compon s a consequence, RCAS1 face, which are thought ion, and metastasis (8,9)	d as an estrogen-in nune response by i (2). RCAS1 is conser- (4). There is eviden- luding cancers of the h studies have show toosis of patients ha arch studies have d dicated that RCAS1 pressed on NK cells is to evade immune obrane Golgi protei 2,7-9). Indeed, it ha of CTLs by negative .). Furthermore, RC, ents of the ER qual induces the depose t to contribute to tu	ducible gene (1), negatively rved in phylogeny ce that tissue ne gastrointestinal wn that levels of rboring the etected elevated was secreted from s, as well as T and B e surveillance (5,6). n with the ability to s been shown that ely regulating AS1 overexpression ity control and ition of tumor-
Background Refer	rences	1. Watanabe, T. et al. (2. Rüder, C. et al. (2009) 3. Tsuchiya, F. et al. (2014) 4. Giaginis, C. et al. (2015) 5. Matsushima, T. et al 6. Nakashima, M. et al 7. Reimer, T.A. et al. (2010) 9. Engelsberg, A. et al.	9) <i>J Clin Invest</i> 119, 001) <i>Biochem Biopl</i> 009) <i>Histol Histopat</i> I. (2001) <i>Blood</i> 98, 3 I. (1999) <i>Nat Med</i> 5, 005) <i>BMC Cancer</i> 5, <i>FASEB J</i> 24, 4000-19	2184-203. hys Res Commun 284, 2- hol 24, 761-76. 13-21. 938-42. 47.	10.	
Species Reactivity	,	Species reactivity is de	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).
Western Blot Buff	er	IMPORTANT: For west TBS, 0.1% Tween® 20		membrane with diluted haking, overnight.	primary antibody i	n 5% w/v BSA, 1X

Applications Key	W: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemistry) FC- FP: Flow Cytometry (Fixed/Permeabilized)	
Cross-Reactivity Key	H: Human M: Mouse R: Rat Mk: Monkey	
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.	
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.	
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.	
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purpose, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.	